Physician profile
Gena E Lyell
NPI 1437173044
$1,374.30
in general payments reported to CMS, 2019-2025
13 companies · $280 in 2025
The $280 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $307 · 2022: $527 · 2023: $160 · 2024: $100 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $430 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $429.51 |
| Education | $110.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $159.55 | 2025 | Arikayce |
| Sk Life Science, INC. | $124.99 | 2022 | |
| Abbvie INC. | $124.99 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.64 | 2022 | |
| Boston Scientific Corporation | $120.61 | 2025 | Watchman Flx |
| Exact Sciences Corporation | $110.77 | 2023 | Cologuard Collection Kit |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $107.63 | 2021 | |
| Alkermes, INC. | $102.96 | 2021 | |
| Neurelis, INC. | $100.46 | 2024 | Valtoco |
| Gilead Sciences, INC. | $96.20 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.20 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $67.41 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $48.89 | 2023 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gena Lyell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.